With the first COVID-19 vaccines beginning to be administered, many across the globe are eagerly watching and waiting, wondering when it will be their turn to receive a vaccination. But due to supply chain, storage and other scalability limitations, not everyone who wants to be vaccinated in the next few months will be able to do so.
That’s one of the reasons it’s so important for researchers to continue developing additional COVID-19 vaccine candidates, even after the first few have been approved for human use.
One such vaccine contender is making its way through its Phase 1 clinical trial, utilizing a vector platform developed by Andrea Amalfitano, dean of the College of Osteopathic Medicine.
Read the full story on the College of Osteopathic Medicine website.